Drugs for Focal Epilepsy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 97)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Gabapentin |
Approved, Investigational |
Phase 4 |
|
60142-96-3 |
3446 |
Synonyms:
1-(Aminomethyl)cyclohexaneacetate
1-(Aminomethyl)cyclohexaneacetic acid
2-[1-(AMINOMETHYL)CYCLOHEXYL]ACETIC ACID
Aclonium
Apo gabapentin
Apo-gabapentin
ApoGabapentin
CI 945
CI 945|Go 3450|GOE 2450|GOE 3450|Neurontin®
CI-945
Convalis
DM-1796
GABAPENTIN
GABAPENTIN GR
Gabapentin hexal
Gabapentin ratiopharm
Gabapentin stada
Gabapentina
Gabapentine
|
Gabapentine [INN-French]
Gabapentino
Gabapentino [INN-Spanish]
Gabapentino [Spanish]
Gabapentin-ratiopharm
Gabapentinum
Gabapentinum [INN-Latin]
Gabapetin
GO 3450
GOE 2450
GOE 3450
GOE-3450
Gralise
Neurontin
Novo gabapentin
Novo-gabapentin
NovoGabapentin
Novo-gabapentine
PMS-Gabapentin
|
|
2 |
|
Oxcarbazepine |
Approved |
Phase 4 |
|
28721-07-5 |
34312 |
Synonyms:
10,11-Dihydro-10-oxo-5H-dibenz(b,F)azepine-5-carboxamide
Desitin brand OF oxcarbazepine
GP-47680
KIN-493
Novartis brand OF oxcarbazepine
OCBZ
Oxcarbamazepine
Oxcarbazepina
|
Oxcarbazepine
Oxcarbazepinum
Oxtellar
OXTELLAR XR
SPN-804
Timox
TRI476
Trileptal
|
|
3 |
|
Stiripentol |
Approved |
Phase 4 |
|
49763-96-4 |
5311454 |
Synonyms:
1-(1,3-BENZODIOXOL-5-YL)-4,4-DIMETHYL-1-PENTEN-3-OL
4,4-DIMETHYL-1-((3,4-METHYLENEDIOXY)PHENYL)-1-PENTEN-3-OL
BCX 2600
BCX-2600
BRN 1313047
|
DIACOMIT
ESTIRIPENTOL
STIRIPENTOL
STIRIPENTOLUM
|
|
4 |
|
Diazepam |
Approved, Illicit, Investigational, Vet_approved |
Phase 4 |
|
439-14-5 |
3016 |
Synonyms:
7-Chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one
Alboral
Aliseum
Alupram
ALUPRAM 10
ALUPRAM 2
ALUPRAM 5
Amiprol
An-Ding
Ansiolin
Ansiolisina
Apaurin
Apo-Diazepam
APOZEPAM
Armonil
Assival
ATENSINE
Atilen
Bensedin
Bialzepam
Calmocitene
Calmpose
Cercine
Ceregulart
DAP
Diacepan
Dialag
DIALAR
DIALAR FTE
Diapam
Diastat
DIASTAT ACUDIAL
Diastat®|LA-III|Valium®|WY-3467
Diazemuls
Diazemulus
Diazepam
DIAZEPAM CIV
DIAZEPAM INTENSOL
Diazepan
Diazetard
Dienpax
Dipam
Dipezona
DIZAC
Domalium
Duksen
Duxen
E-PAM
Eridan
Eurosan
Evacalm
Faustan
Faustan,
Freudal
Frustan
Gewacalm
Gihitan
Kabivitrum
Kiatrium
LA III
LA-III
Lamra
Lembrol
Levium
Liberetas
Mandrozep
Methyl diazepinone
Methyldiazepinone
Morosan
|
Neurolytril
Noan
Novazam
Novo-Dipam
NRL-1
NSC-169897
NSC-77518
Paceum
Pacitran
Paranten
Paxate
PAXEL
Plidan
Pms-Diazepam
Pro-Pam
Q-PAM
Q-Pam Relanium
Quetinil
Quiatril
Quievita
Relaminal
Relanium
Renborin
RO-52807
RO-5-2807
Ruhsitus
Saromet
SCRIPTOPAM
Sedapam
Sedipam
Seduksen
Seduxen
SERENACK
Serenamin
Serenzin
Servizepam
Setonil
Sibazon
Sibazone
SOLIS
Sonacon
Stesolid
Stesolin
TENSIUM
Tensopam
TRANIMUL
Tranqdyn
Tranquase
Tranquirit
Tranquo-Puren
Tranquo-Tablinen
Umbrium
Unisedil
Usempax Ap
Valaxona
VALCLAIR
Valeo
Valiquid
Valitran
Valium
VALRELEASE
Vatran
Velium
Vival
VIVOL
WY-3467
Zetran
Zipan
|
|
5 |
|
Levetiracetam |
Approved |
Phase 4 |
|
102767-28-2 |
441341 5284583 |
Synonyms:
AGB-101
alpha Ethyl 2 oxo 1 pyrrolidineacetamide
alpha-Ethyl-2-oxo-1-pyrrolidineacetamide
DESITREND
e Keppra
ELEPSIA XR
Etiracetam
Etiracetam, R isomer
Etiracetam, R-isomer
Etiracetam, S isomer
Etiracetam, S-isomer
Keppra
KEPPRA XR
Keppra®|Spritam®|UCB L059|UCB-L 059
LEVETIRACETAM
Levetiracetam [INN]
LEVETIRACETAM IN SODIUM CHLORIDE
|
Levetiracetame
Levetiracetamum
Levetiracetamum [INN-Latin]
Levitiracetam
MATEVER
N03AX14
R-Isomer etiracetam
S-Isomer etiracetam
SPRITAM
UCB brand OF levetiracetam
Ucb L059
Ucb L060
UCB-22059
Ucb-L059
UcbL060
Ucb-L060
|
|
6 |
|
Lamotrigine |
Approved, Investigational |
Phase 4 |
|
84057-84-1 |
3878 |
Synonyms:
3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine
BW 430C
BW-430C
Crisomet
GIZORD
GW 273293
Labileno
Lamictal
LAMICTAL CD
LAMICTAL ODT
|
LAMICTAL XR
Lamictal®
Lamictin
Lamiktal
Lamotrigina
Lamotrigina [Spanish]
Lamotrigine
Lamotriginum
Lamotriginum [Latin]
QIN
QÍN
|
|
7 |
|
Pregabalin |
Approved, Investigational |
Phase 4 |
|
148553-50-8 |
5486971 |
Synonyms:
(R-)-3-Isobutyl gaba
(S)-3-(Aminomethyl)-5-methylhexanoic acid
(S)-3-Isobutyl gaba
(S)-PREGABALIN
(S+)-3-isobutyl gaba
3 Isobutyl gaba
3-(Aminomethyl)-5-methylhexanoic acid
3-Isobutyl gaba
ALZAIN
AXALID
CI 1008
CI-1008
|
GABA, 3-isobutyl
LECAENT
Lyrica
LYRICA CR
NERVALIN
PD 144723
PD-144723
PREGABALIN
Pregabalina
REWISCA
S-(+)-3-ISOBUTYLGABA
YNP-1807
|
|
8 |
|
Zonisamide |
Approved, Investigational |
Phase 4 |
|
68291-97-4 |
5734 |
Synonyms:
1,2-Benzisoxazole-3-methanesulfonamide
1,2-Benzisoxazole-3-methanesulphonamide
3 Sulfamoylmethyl 1,2 benzisoxazole
3-(Sulfamoylmethyl)-1,2-benzisoxazole
3-(Sulphamoylmethyl)-1,2-benzisoxazole
3-Sulfamoylmethyl-1,2-benzisoxazole
AD-810
AD-810|CI-912|PD-110843|Zonegran®
Benzo[D]isoxazol-3-yl-methanesulfonamide
Benzo[D]isoxazol-3-yl-methanesulphonamide
CI-912
Elan brand OF zonisamide
|
Exceglan
Excegram
Excegran
PD-110843
Zonegran
Zonisamida
Zonisamida [Spanish]
Zonisamide
Zonisamide monosodium
Zonisamidum
Zonisamidum [Latin]
|
|
9 |
|
Topiramate |
Approved |
Phase 4 |
|
97240-79-4 |
5284627 |
Synonyms:
[(1R,2S,6S,9R)-4,4,11,11-TETRAMETHYL-3,5,7,10,12-PENTAOXATRICYCLO[7.3.0.0^{2,6}]DODECAN-6-YL]METHYL SULFAMATE
2,3:4,5-Bis-O-(1-methylethylidene)-b-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-b-D-fructopyranose sulfamic acid
2,3:4,5-Bis-O-(1-methylethylidene)-b-D-fructopyranose sulphamate
2,3:4,5-Bis-O-(1-methylethylidene)-b-D-fructopyranose sulphamic acid
2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamic acid
2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulphamate
2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulphamic acid
2,3:4,5-Bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamic acid
2,3:4,5-Bis-O-(1-methylethylidene)-β-D-fructopyranose sulphamate
2,3:4,5-Bis-O-(1-methylethylidene)-β-D-fructopyranose sulphamic acid
2,3:4,5-Di-O-isopropylidene-b-D-fructopyranose sulfamate
2,3:4,5-Di-O-isopropylidene-b-D-fructopyranose sulfamic acid
2,3:4,5-Di-O-isopropylidene-b-D-fructopyranose sulphamate
2,3:4,5-Di-O-isopropylidene-b-D-fructopyranose sulphamic acid
2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate
2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamic acid
2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulphamate
2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulphamic acid
2,3:4,5-Di-O-isopropylidene-β-D-fructopyranose sulfamate
2,3:4,5-Di-O-isopropylidene-β-D-fructopyranose sulfamic acid
2,3:4,5-Di-O-isopropylidene-β-D-fructopyranose sulphamate
2,3:4,5-Di-O-isopropylidene-β-D-fructopyranose sulphamic acid
2,3-4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
|
Epitomax
epitomax|Eprontia® (liquid formulation)|MCN-4853|RWJ-17021|Topamax®
MCN-4853
QUDEXY XR
RWJ-17021
RWJ-17021-000
Tipiramate
Tipiramate [French]
Tipiramato
Tipiramato [Spanish]
Tipiramic acid
Topamax
Topamax sprinkle
TOPIRAMATE
topiramate tablet
Topiramato
Topiramato [INN-Spanish]
Topiramatum
Topiramatum [INN-Latin]
Topiramic acid
Topomax
TPM
Trokendi XR
USL255
USL-255
|
|
10 |
|
Tiagabine |
Approved, Investigational |
Phase 4 |
|
115103-54-3 |
60648 |
Synonyms:
(-)-(R)-1-(4,4-Bis(3-methyl-2-thienyl)-3-butenyl)nipecotate
(-)-(R)-1-(4,4-Bis(3-methyl-2-thienyl)-3-butenyl)nipecotic acid
(-)-(R)-1-[4,4-Bis(3-methyl-2-thienyl)-3-butenyl]nipecotate
(-)-(R)-1-[4,4-Bis(3-methyl-2-thienyl)-3-butenyl]nipecotic acid
(R)-(-)-1-[4,4-Bis(3-methyl-2-thienyl)-3-butenyl]nipecotate
(R)-(-)-1-[4,4-Bis(3-methyl-2-thienyl)-3-butenyl]nipecotic acid
(R)-(4,4-Bis(3-methyl-2-thienyl)-3-butenyl)-3-piperidinecarboxylic acid, hydrochloride
(R)-Tiagabine
A-70569-1
ABBOTT-70569
ABBOTT-70569 FREE BASE
ABBOTT-70569|ABT-569|Gabitril®|tiagabine hydrochloride
ABBOTT-70569-1
ABBOTT-705691 FREE BASE
|
ABT-569
ABT-569 FREE BASE
Gabitril
N-(4,4-Di(3-methylthien-2-yl)but-3-enyl)nipecotic acid
NNC-05-0328
NNC-050328 FREE BASE
NO-05-0328
NO-050328 FREE BASE
Tiagabina
TIAGABINE
Tiagabine hydrochloride
Tiagabine, (S)-isomer
Tiagabinum
|
|
11 |
|
Eslicarbazepine acetate |
Approved |
Phase 4 |
|
236395-14-5 |
179344 |
Synonyms:
(10S)-10-ACETOXY-10,11-DIHYDRO-5H-DIBENZ[B,F]AZEPINE-5-CARBOXAMIDE
(10S)-5-CARBAMOYL-10,11-DIHYDRO-5H-DIBENZO[B,F]AZEPIN-10-YL ACETATE
APTIOM
BIA-2093
BIA-2-093
ERELIB
|
ESL
ESLICARBAZEPINE ACETATE
PAZZUL
SEP-0002093
STEDESA
ZEBINIX
|
|
12 |
|
Lacosamide |
Approved |
Phase 4 |
|
175481-36-4 |
21634109 219078 |
Synonyms:
ADD 234037
ADD 234037|erlosamide|harkeroside|SPM 927|Vimpat®
ADD-243037
ERLOSAMIDE
HARKEROSIDE
HARKOSERIDE
Lacosamida
|
Lacosamide
N-Benzyl-2-[(1-hydroxyethylidene)amino]-3-methoxypropanimidate
N-Benzyl-2-acetamido-3-methoxypropionamide
N-Benzyl-acmeoprnh2
SPM 927
SPM-927
Vimpat
|
|
13 |
|
Valproic acid |
Approved, Investigational |
Phase 4 |
|
99-66-1 |
3121 |
Synonyms:
(N-C3H7)2chcooh
(S)-2-Propyl-4-pentanoate
(S)-2-Propyl-4-pentanoic acid
2 Propylpentanoic acid
2-N-PROPYL-4-PENTENOIC ACID
2-N-Propyl-N-valerate
2-N-Propyl-N-valeric acid
2-Propylpentanoate
2-PROPYL-pentanoate
2-Propylpentanoic acid
2-PROPYL-pentanoIC ACID
2-Propylvalerate
2-Propylvaleric acid
44089
4-Heptanecarboxylate
4-Heptanecarboxylic acid
A-44090
A-44090|Depakote®|Epilim®|valproate sodium
Acetate, dipropyl
Acid, propylisopropylacetic
Acid, valproic
Acide valproique
acide valproïque
Acido valproico
ácido valproico
Acidum valproicum
Alti-valproic
Apo-divalproex
Apo-valproic
Apo-valproic syrup
Avugane
Baceca
Calcium valproate
Calcium, valproate
Convulex
Convulsofin
Delepsine
Depacon
Depakene
Depakin
Depakin chrono
Depakine
Depakine chrono
Depakote
Deproic
Di-N-propylacetate
Di-N-propylacetic acid
Di-N-propylessigsaeure
Di-N-propylessigsaure
Di-n-propylessigsäure
Dipropyl acetate
Dipropylacetate
Dipropylacetic acid
Divalproex
Divalproex sodium
DOM-divalproex
Dom-valproate
DOM-valproic
Dom-valproic acid
DOM-valproic acid e.c.
Dom-valproic acid syrup
DPA
Epiject i.v.
Epilex
Epilim
|
Epival
Epival er
Ergenyl
Gen-divalproex
Kyselina 2-propylvalerova
LEP321
Magnesium valproate
Med valproic
Mylproin
Myproate
Myproic acid
N-Dipropylacetic acid
N-DPA
Novo-divalproex
Novo-valproic
Novo-valproic - ecc
Novo-valproic soft gel cap
NSC-93819
Nu-valproic
PEAC
Penta-valproic
PHL-Valproate
PHL-Valproic acid
PHL-Valproic acid e.c.
PMS-Divalproex
PMS-Valproate
PMS-Valproic acid
PMS-Valproic acid e.c.
Propylisopropylacetic acid
Propylvaleric acid
Ratio-valproic - ecc
S(-)-4-En-valproate
S(-)-4-En-valproic acid
S-2-N-Propyl-4-pentenoate
S-2-N-Propyl-4-pentenoic acid
Sandoz valproic
Savicol
Semisodium valproate
Sodium hydrogen divalproate
Sodium valproate
Sodium, divalproex
Sodium, valproate
Sprinkle
STAVZOR
Valcote
Valparin
Valproate
Valproate calcium
Valproate semisodique [French]
Valproate semisodium
Valproate sodium
Valproate, calcium
Valproate, magnesium
Valproate, semisodium
Valproate, sodium
Valproato semisodico [Spanish]
Valproatum seminatricum [Latin]
VALPROIC ACID
Valproic acid usp
Valproic acid USP24
Valproic acid, sodium salt (2:1)
Valproinsaeure
Valproinsäure
VPA
Vupral
|
|
14 |
|
Clobazam |
Approved, Illicit |
Phase 4 |
|
22316-47-8 |
2789 |
Synonyms:
1-Phenyl-5-methyl-8-chloro-1,2,4,5- tetrahydro-2,4-diketo-3H-1,5-benzodiazepine
1-Phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-dioxo-3H-1,5-benzodiazepine
7-Chloro-1-methyl-5-phenyl-1,5-dihydro-benzo[b][1,4]diazepine-2,4-dione
Chlorepin
CLOBAZAM
Clobazamum
Clorepin
Frisium
H-4723
HR-376
|
LM-2717
Mystan
NSC-336279
Onfi
PERIZAM
SYMPAZAN
TAPCLOB
Urbadan
URBANOL
Urbanyl
|
|
15 |
|
Phenobarbital |
Approved, Investigational |
Phase 4 |
|
50-06-6 |
4763 |
Synonyms:
5-Ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione
5-Ethyl-5-phenylbarbitate
5-Ethyl-5-phenylbarbitic acid
5-Ethyl-5-phenylbarbituric acid
5-Ethyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione
5-Ethyl-5-phenyl-pyrimidine-2,4,6-trione
5-Phenyl-5-ethylbarbitate
5-Phenyl-5-ethylbarbitic acid
5-Phenyl-5-ethylbarbituric acid
Acid, phenylethylbarbituric
Adonal
Aephenal
Agrypnal
Amylofene
Aphenylbarbit
Aphenyletten
Barbenyl
Barbinal
Barbiphen
Barbiphenyl
Barbipil
Barbita
Barbivis
Barbonal
Barbophen
Bardorm
Bartol
Bialminal
Blu-Phen
Cabronal
Calmetten
Calminal
Cardenal
Chinoin
Codibarbita
Coronaletta
Cratecil
Damoral
Dezibarbitur
Dormina
Dormiral
Dormital
Doscalun
Duneryl
Ensobarb
Ensodorm
Epanal
Epidorm
Epilol
Episedal
Epsylone
ESKABARB
Etilfen
Euneryl
Fenbital
Fenemal
Fenobarbital
fenobarbital|Luminal®|phenobarb|phenobarbital sodium|phenobarbitone|phenylethylbarbiturate
Fenosed
Fenylettae
Gardenal
Gardepanyl
Glysoletten
Haplopan
Haplos
Helional
Hennoletten
Henotal
Hypnaletten
Hypnette
Hypnogen
Hypnolone
Hypnoltol
Hypno-Tablinetten
Hysteps
Lefebar
Leonal
Lephebar
Lepinal
Lepinaletten
Linasen
Liquital
Lixophen
Lubergal
Lubrokal
Lumen
Lumesettes
|
Lumesyn
Luminal
Lumofridetten
Luphenil
Luramin
Molinal
Monosodium salt phenobarbital
Neurobarb
Nirvonal
NOPTIL
Nova-Pheno
NSC-128143
NSC-128143-
NSC-9848
Nunol
Parkotal
Pharmetten
Phenaemal
Phen-Bar
Phenemal
Phenemalum
Phenobal
PHENOBARBITAL
PHENOBARBITAL CIV
Phenobarbital sodium
Phenobarbital, monosodium salt
Phenobarbitate
Phenobarbitic acid
Phenobarbitol
Phenobarbitone
Phenobarbituric acid
Phenobarbyl
Phenoluric
Phenolurio
Phenomet
Phenonyl
Phenoturic
Phenylaethylbarbitursaeure
Phenyläthylbarbitursäure
Phenylbarbital
Phenylethylbarbitate
Phenylethylbarbitic acid
Phenylethylbarbiturate
Phenylethylbarbituric acid
Phenylethylbarbitursaeure
Phenylethylbarbitursäure
PHENYLETHYLMALONYLUREA
Phenyletten
Phenyral
Phob
Polcominal
Promptonal
Sedabar
Seda-Tablinen
Sedicat
Sedizorin
Sedlyn
Sedofen
Sedonal
Sedonettes
Sevenal
Sinoratox
Sodium, phenobarbital
SOLFOTON
Solfoton Talpheno
Solu-Barb
Sombutol
Somnolens
Somnoletten
Somnosan
Somonal
Spasepilin
Starifen
Starilettae
Stental
Stental Extentabs
TALPHENO
Teolaxin
Teoloxin
Thenobarbital
Theoloxin
Triabarb
Tridezibarbitur
Triphenatol
Versomnal
Zadoletten
Zadonal
|
|
16 |
|
GABA Agonists |
|
Phase 4 |
|
|
|
17 |
|
Excitatory Amino Acid Antagonists |
|
Phase 4 |
|
|
|
18 |
|
Hypoglycemic Agents |
|
Phase 4 |
|
|
|
19 |
|
GABA Modulators |
|
Phase 4 |
|
|
|
20 |
|
Antiemetics |
|
Phase 4 |
|
|
|
21 |
|
Anesthetics, Intravenous |
|
Phase 4 |
|
|
|
22 |
|
Anesthetics, General |
|
Phase 4 |
|
|
|
23 |
|
Anesthetics |
|
Phase 4 |
|
|
|
24 |
|
Hypnotics and Sedatives |
|
Phase 4 |
|
|
|
25 |
|
Gastrointestinal Agents |
|
Phase 4 |
|
|
|
26 |
|
Hormones |
|
Phase 4 |
|
|
|
27 |
|
Anti-Anxiety Agents |
|
Phase 4 |
|
|
|
28 |
|
Psychotropic Drugs |
|
Phase 4 |
|
|
|
29 |
|
Calcium, Dietary |
|
Phase 4 |
|
|
|
30 |
|
calcium channel blockers |
|
Phase 4 |
|
|
|
31 |
|
Analgesics |
|
Phase 4 |
|
|
|
32 |
|
Calcium |
Nutraceutical |
Phase 4 |
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
33 |
|
Benzocaine |
Approved, Investigational |
Phase 3 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
34 |
|
Tannic acid |
Approved |
Phase 3 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
35 |
|
Cenobamate |
Approved, Investigational |
Phase 3 |
|
913088-80-9 |
11962412 |
Synonyms:
[(1R)-1-(2-Chlorophenyl)-2-(2H-1,2,3,4-tetrazol-2-yl)ethoxy]carboximidate
Carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester
CENOBAMATE
Cénobamate
Cenobamato
Cenobamatum
|
Cenobamic acid
Ontozry®|Xcopri®|YKP-3089|YKP3089
XCOPRI
YKP3089
YKP-3089
|
|
36 |
|
Carbamazepine |
Approved, Investigational |
Phase 3 |
|
298-46-4 |
2554 |
Synonyms:
5-Carbamoyl-5H-dibenz(b,F)azepine
5-Carbamoyl-5H-dibenz[b,F]azepine
5-Carbamoyl-5H-dibenzo(b,F)azepine
5-Carbamyl-5H-dibenzo(b,F)azepine
5H-Dibenz(b,F)azepine-5-carboxamide
Amizepine
Apo-Carbamazepine
ARBIL MR
Atretol
Biston
CALEPSIN
calepsin|Carnexiv®|Tegretol®
CARBAGEN SR
Carbamazepen
Carbamazepin
Carbamazepina
Carbamazepine
Carbamazépine
Carbamazepine acetate
Carbamazepine anhydrous
Carbamazepine dihydrate
Carbamazepine hydrochloride
Carbamazepine L-tartrate (4:1)
Carbamazepine phosphate
Carbamazepine sulfate (2:1)
Carbamazepinum
Carbamezepine
CARBATROL
Carbazepin
Carbazepine
Carbelan
Carnexiv
CBZ
EPIMAZ
|
EPIMAZ RET
Epitol
Equetro
Finlepsin
G-32883
GEIGY 32883
Karbamazepin
Lexin
Neurotol
Novo-Carbamaz
NSC-169864
Nu-Carbamazepine
Sirtal
SIRTAL RET
Stazepin
Stazepine
Taro-Carbamazepine
Taro-Carbamazepine Cr
TEG111
Tegretal
Tegretol
TEGRETOL CHEWTAB
Tegretol Chewtabs
Tegretol Cr
TEGRETOL PROLONGED RELEASE
TEGRETOL XR
TEGRETOL-XR
Telesmin
TERIL
TERIL RET
Timonil
TIMONIL 200 RET
TIMONIL 400 RET
|
|
37 |
|
Aspartic acid |
Approved, Nutraceutical |
Phase 3 |
|
56-84-8 |
5960 |
Synonyms:
(+)-Aspartate
(+)-Aspartic acid
(+-)-Aspartic acid
(2S)-2-AMINOBUTANEDIOIC ACID
(2S)-2-AMINOSUCCINIC ACID
(2S)-Aspartate
(2S)-Aspartic acid
(L)-Aspartate
(L)-Aspartic acid
(R)-2-Aminosuccinate
(R,S)-Aspartic acid
(S)-(+)-Aspartate
(S)-(+)-Aspartic acid
(S)-2-Aminobutanedioate
(S)-2-Aminobutanedioic acid
(S)-2-Aminosuccinate
(S)-2-Aminosuccinic acid
(S)-Aminobutanedioate
(S)-Amino-butanedioate
(S)-Aminobutanedioic acid
(S)-Amino-butanedioic acid
(S)-Aspartate
(S)-Aspartic acid
[<sup>3</sup>H]-L-aspartate|[<sup>3</sup>H]-L-aspartic acid
2-Amino-3-methylsuccinate
2-Amino-3-methylsuccinic acid
2-Aminosuccinate
2-Aminosuccinic acid
ácido aspártico
Acidum asparticum
alpha-Aminosuccinate
alpha-Aminosuccinic acid
Aminosuccinate
Ammonium aspartate
Asp
Asparagate
Asparagic acid
Asparaginate
Asparaginic acid
Asparatate
ASPARTate
Aspartate magnesium hydrochloride
Aspartate, ammonium
Aspartate, calcium
Aspartate, dipotassium
Aspartate, disodium
Aspartate, magnesium
Aspartate, monopotassium
Aspartate, monosodium
Aspartate, potassium
Aspartate, sodium
|
ASPARTIC ACID
Aspartic acid, ammonium salt
Aspartic acid, calcium salt
Aspartic acid, dipotassium salt
Aspartic acid, disodium salt
Aspartic acid, hydrobromide
Aspartic acid, hydrochloride
Aspartic acid, magnesium (1:1) salt, hydrochloride, trihydrate
Aspartic acid, magnesium (2:1) salt
Aspartic acid, magnesium-potassium (2:1:2) salt
Aspartic acid, monopotassium salt
Aspartic acid, monosodium salt
Aspartic acid, potassium salt
Aspartic acid, sodium salt
Calcium aspartate
D
Dipotassium aspartate
Disodium aspartate
FEMA NO. 3656
H-Asp-OH
Hydrobromide aspartic acid
Hydrochloride aspartic acid
Hydrochloride, aspartate magnesium
L Aspartate
L Aspartic acid
L-(+)-Aspartate
L-(+)-Aspartic acid
L-Aminosuccinate
L-Aminosuccinic acid
L-Asp
L-Asp|L-aspartate
L-Asparagate
L-Asparagic acid
L-Asparaginate
L-Asparaginic acid
L-Asparaginsaeure
L-Asparaginsäure
L-Aspartate
L-Aspartic acid
Magnesiocard
Magnesium aspartate
MG 5 Longoral
MG5Longoral
MG-5-Longoral
Monopotassium aspartate
Monosodium aspartate
NSC-3973
Poly-DL-succinimide
Polysuccinimide
Potassium aspartate
Sodium aspartate
|
|
38 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
39 |
|
N-Methylaspartate |
|
Phase 3 |
|
|
|
40 |
|
Antipsychotic Agents |
|
Phase 3 |
|
|
|
41 |
|
Sodium Channel Blockers |
|
Phase 3 |
|
|
|
42 |
|
Neurotransmitter Agents |
|
Phase 3 |
|
|
|
43 |
|
Anticonvulsants |
|
Phase 3 |
|
|
|
44 |
|
Nootropic Agents |
|
Phase 3 |
|
|
|
45 |
|
Diuretics, Potassium Sparing |
|
Phase 3 |
|
|
|
46 |
|
D-Leucine |
Experimental, Investigational, Nutraceutical |
Phase 3 |
|
328-38-1, 61-90-5 |
439524 6106 |
Synonyms:
(2R)-2-Amino-4-methylpentanoate
(2R)-2-Amino-4-methylpentanoic acid
(2S)-2-Amino-4-methylpentanoate
(2S)-2-Amino-4-methylpentanoic acid
(2S)-2-AMINO-4-METHYL-PENTANOIC ACID
(2S)-a-2-Amino-4-methylvalerate
(2S)-a-2-Amino-4-methylvaleric acid
(2S)-a-Leucine
(2S)-alpha-2-Amino-4-methylvalerate
(2S)-alpha-2-Amino-4-methylvaleric acid
(2S)-alpha-Leucine
(2S)-Α-2-amino-4-methylvalerate
(2S)-Α-2-amino-4-methylvaleric acid
(2S)-Α-leucine
(R)-(−)-leucine
(R)-(-)-Leucine
(R)-Leucine
(S)-(+)-Leucine
(S)-2-Amino-4-methylpentanoate
(S)-2-Amino-4-methylpentanoic acid
(S)-2-Amino-4-methylvalerate
(S)-2-Amino-4-methylvaleric acid
(S)-Leucine
2-Amino-4-methylvalerate
2-Amino-4-methylvaleric acid
4-Methyl-L-norvaline
|
D-2-Amino-4-methylvalerate
D-2-Amino-4-methylvaleric acid
DLE
D-Leucin
D-Leuzin
E641
FEMA NO. 3297
L
L-(+)-Leucine
L-a-Aminoisocaproate
L-a-Aminoisocaproic acid
L-alpha-Aminoisocaproate
L-alpha-Aminoisocaproic acid
Leu
LEUCINE
Leucine, L isomer
Leucine, L-isomer
LEUCOVORIN
L-Isomer leucine
L-LEU
L-Leucin
L-LEUCINE
L-Leuzin
L-Α-AMINOISOCAPROIC ACID
NSC-46709
|
|
47 |
|
Brivaracetam |
Approved, Investigational |
Phase 2 |
|
357336-20-0 |
9834332 9837243 |
Synonyms:
2-(2-OXO-4-PROPYLPYRROLIDIN-1-YL)BUTANAMIDE
2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide|Briviact®|compound 83α|UCB 34714|UCB-34714|UCB34714
2-(2-oxo-4-Propylpyrrolidin-1-yl)butanimidate
BRIVARACETAM
BRIVIACT
|
COMPOUND 83Α
UCB 34714
UCB34714
UCB-34714
|
|
48 |
|
Natalizumab |
Approved, Investigational |
Phase 2 |
|
189261-10-7 |
|
Synonyms:
AN100226|anti-alpha4 integrin|anti-VLA4|Tysabri®
AN100226M
ANTEGRAN
ANTI-ALPHA4 INTEGRIN
|
ANTI-VLA4
NATALIZUMAB
TYSABRI
|
|
49 |
|
Ganaxolone |
Approved, Investigational |
Phase 2 |
|
38398-32-2 |
22023730 6918305 |
Synonyms:
CCD-1042
CCD-1042|CCD1042|Ztalmy®
|
|
|
50 |
|
Nifedipine |
Approved |
Phase 2 |
|
21829-25-4 |
4485 |
Synonyms:
4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsaeuredimethylester
4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester
Adalat
Adalat 10
Adalat 20
Adalat 5
ADALAT A.R.
ADALAT CC
Adalat CR
Adalat Crono
Adalat Ft
Adalat Gits
Adalat Gits 30
ADALAT IC
Adalat LA
ADALAT LA 20
ADALAT LA 30
ADALAT LA 60
Adalat LP
Adalat Oros
Adalat PA
ADALAT RET
Adalat Retard
Adalat®|BAY-A-1040|Procardia®
Adalate
ADALATE LP
ADANIF XL
Adapine
Adapress
Adcock ingram brand OF nifedipine
ADIPINE
ADIPINE MR 10
ADIPINE MR 20
ADIPINE XL
Afeditab CR
Alat
Aldipin
Alfadal
Alonix
Alonix S
Alpha-Nifedipine Retard
ANGIOPINE 10
ANGIOPINE 40 LA
ANGIOPINE 5
ANGIOPINE MR 10
ANGIOPINE MR 20
Angipec
Anifed
Anpine
Apo-Nifed
Aprical
AWD pharma brand OF nifedipine
BAY a 1040
BAY-a-1040
Bayer brand OF nifedipine
Bonacid
CALANIF
CALCHAN MR 10
CALCHAN MR 20
Calcibloc
Calcigard
CALCILAT
Camont
Cardifen
Cardilat
CARDILATE MR
Cardionorm
Chronadalate
Chronadalate Lp
Citilat
Coracten
CORACTEN SR
CORACTEN XL
Coral
Cordafen
Cordaflex
Cordalat
Cordicant
Cordilan
Cordipin
Cordipine
Corinfar
CORODAY MR
Corotrend
Corynphar
Depin
Dignokonstant
Dilafed
Dilcor
Dipinkor
Duranifin
Ecodipi
Ecodipin
Ecodipin E
|
Fedcor
Fedcor Retard
Fenamon
Fenamon Sr
Fenigidin
Fenihidin
Fenihidine
FORTIPINE LA40
GENALAT 10 RET
GENALAT 20 RET
Glopir
Hadipin
Hexadilat
HYPOLAR RET 10
HYPOLAR RET 20
HYPOLAR XL 30
Introcar
KENTIPINE
KENTIPINE MR 10
KENTIPINE MR 20
Kordafen
Korinfar
KRKA brand OF nifedipine
Macorel
Megalat
Monohydrochloride, nifedipine
Myogard
N1fedilat
Nedipin
NEOZIPINE XL
Nicardia
Nifangin
Nifar
Nifdemin
Nifebene
Nifecard
Nifecor
Nifedepat
Nifedicor
Nifedin
Nifedine
NIFEDIPINE
Nifedipine bayer brand
Nifedipine gtis
Nifedipine krka brand
Nifedipine monohydrochloride
Nifedipine orion brand
Nifedipine pfizer brand
Nifedipine Retard
Nifedipine-gtis
Nifedipino
Nifedipinum
Nifedipres
NIFEDIPRESS MR 10
NIFEDIPRESS MR 20
Nifedirex LP
NIFEDOTARD 20 MR
Nifelan
Nifelat
Nifelat Q
Nifelate
NIFELEASE
NIFENSAR XL
NIFE-WOLFF
Nificard
Nifidine
Nifipen
NIFOPRESS MR
NIFOPRESS RET
NIMODREL MR 10
NIMODREL MR 20
NIMODREL XL
Niphedipine
NIVATEN RET
Orion brand OF nifedipine
Orix
Oxcord
Pfizer brand OF nifedipine
Pidilat
Procardia
Procardia XL
Sepamit
SLOFEDIPINE XL 30
SLOFEDIPINE XL 60
TENSIPINE MR 10
TENSIPINE MR 20
Tibricol
UNIPINE XL
VALNI 20 RET
VALNI XL
VASAD
Vascard
Zenusin
|
|
Interventional clinical trials:
(show top 50)
(show all 230)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Prospective Open Label Evaluation of Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy: A Pilot Study |
Unknown status |
NCT02726919 |
Phase 4 |
Clobazam |
2 |
Efficacy and Tolerability of Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy (STANDLOW). A Multicenter, Randomized, Single-blind, Parallel-group Trial |
Unknown status |
NCT03689114 |
Phase 4 |
Low dose carbamazepine;Standard dose carbamazepine;Low dose levetiracetam;Standard dose levetiracetam;Low dose valproate;Standard dose valproate;Low dose zonisamide;Standard dose zonisamide;Low dose oxcarbazepine;Standard dose oxcarbazepine;Low dose topiramate;Standard dose topiramate;Low dose lamotrigine;Standard dose lamotrigine;Low dose gabapentin;Standard dose gabapentin |
3 |
Liceo Study: A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice |
Completed |
NCT00855738 |
Phase 4 |
Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide |
4 |
A Multicentre, Double-blind, Randomized, Phase IV Clinical Trial Comparing the Safety, Tolerability and Efficacy of Levetiracetam Versus Lamotrigine and Carbamazepine in the Oral Antiepileptic Therapy of Newly Diagnosed Elderly Patients With Focal Epilepsy. |
Completed |
NCT00438451 |
Phase 4 |
Levetiracetam;Carbamazepine;Lamotrigine |
5 |
Efficacy and Safety of Rapid Titration Protocols of Lacosamide: An Exploratory Study |
Completed |
NCT03607851 |
Phase 4 |
Lacosamide - conventional titration;Lacosamide - rapid titration 1;Lacosamide - rapid titration 2 |
6 |
The Effects on Cognitive Function of Levetiracetam (Keppra®) Compared to Carbamazepine (Tegretol®, Carmazepine®) as Monotherapy for Children With Partial Seizure; A Multicentric Randomized Controlled Study |
Completed |
NCT02208492 |
Phase 4 |
Levetiracetam;Carabamazepine |
7 |
Searching for "Sleep Friendly" Therapies for a Sleepy Population: A Double-Blind, Placebo-Controlled, Randomized Trial to Assess the Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy |
Completed |
NCT01190098 |
Phase 4 |
Lacosamide;Placebo |
8 |
A Phase IV, Open-label, Multi-center Trial to Evaluate the Safety and Efficacy of Keppra® After Conversion to Mono-therapy in Adult Subjects With Partial Epilepsy |
Completed |
NCT00630357 |
Phase 4 |
Levetiracetam (Keppra) |
9 |
Trial Studying the Safety and Efficacy of Keppra® as Adjunctive Therapy in Adult Patients With Uncontrolled Partial Epilepsy |
Completed |
NCT00630968 |
Phase 4 |
Levetiracetam (Keppra) |
10 |
A Phase IV, Open-label, Multi-center, Community-based Trial in Asia Studying the Safety and Efficacy of Keppraâ„¢ as Adjunctive Therapy in Adult Subjects With Uncontrolled Partial Epilepsy. |
Completed |
NCT00160654 |
Phase 4 |
Levetiracetam |
11 |
A Korean Open-label, Multi-center, Community-based Trial Assessing the Efficacy and Safety of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy |
Completed |
NCT01140867 |
Phase 4 |
zonisamide |
12 |
A Multi-Center, Open-label, Randomized Study to Evaluate the Long Term Effectiveness of Levetiracetam as Monotherapy in Comparison With Oxcarbazepine in Subjects With Newly or Recently Diagnosed Partial Epilepsy |
Completed |
NCT01498822 |
Phase 4 |
Levetiracetam;Oxcarbazepine |
13 |
Phase IV Study of Cognitive and Behavioral Effects of Lacosamide as Adjunctive Therapy in Patients With Partial Epilepsy |
Completed |
NCT01175954 |
Phase 4 |
Lacosamide |
14 |
A Randomized, Double-blind, Parallel-group Multi-center Comparative Flexible-dose Trial Of Pregabalin Versus Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures. |
Completed |
NCT00537940 |
Phase 4 |
Pregabalin;Gabapentin |
15 |
PROSPECTIVE RANDOMIZED 12-WEEK CONTROLLED STUDY OF VISUAL FIELD CHANGE IN SUBJECTS WITH PARTIAL SEIZURES RECEIVING PREGABALIN OR PLACEBO |
Completed |
NCT00351611 |
Phase 4 |
Lyrica (pregabalin);placebo |
16 |
TOPAMAX� (Topiramate) Initiated as Monotherapy in Epilepsy (TIME): A Multicenter, Outpatient, Open-Label, Study to Evaluate the Dosing, Effectiveness and Safety of TOPAMAX� as Monotherapy in the Treatment of Epilepsy in Clinical Practice |
Completed |
NCT00266604 |
Phase 4 |
Topiramate |
17 |
A Randomized, Single-dose, Parallel-group Study to Evaluate the Pharmacokinetic Profiles of Two Formulation of Pregabalin in Healthy Volunteers Under Fasting Conditions |
Completed |
NCT03712475 |
Phase 4 |
Pregabalin |
18 |
Pharmacovigilance Study of Keppra. SPAIN - SKATE : Safety of Keppra as Adjunctive Therapy in Epilepsy |
Completed |
NCT00643500 |
Phase 4 |
Levetiracetam |
19 |
An Open-Label, Multicenter, Multinational Study of Lacosamide as First Add-On Anti-epileptic Drug (AED) Treatment in Subjects With Partial-Onset Seizures |
Completed |
NCT00955357 |
Phase 4 |
Lacosamide |
20 |
9-11 Week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Determine Effects of Adjunctive Levetiracetam on Sleep Architecture of Adults With Partial Onset Epilepsy Receiving a First Generation Anti-epileptic Drug. |
Completed |
NCT00245713 |
Phase 4 |
levetiracetam |
21 |
A 24-Week Prospective, Open-Label, Multicenter Study to Evaluate the Effect on Seizure Frequency, Safety and Tolerability of Oxcarbazepine Monotherapy in Adult Patients With Partial Seizures |
Completed |
NCT00275925 |
Phase 4 |
Oxcarbazepine |
22 |
A 24-week Prospective Open-label Multicenter Study to Evaluate the Effect on Seizure Frequency, Safety and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures |
Completed |
NCT00275912 |
Phase 4 |
Oxcarbazepine |
23 |
A Multicenter, Open Label Study to Evaluate the Tolerability, Safety and Efficacy of Lacosamide (200mg - 400mg/Day) as add-on Therapy for Patients With Partial Onset Epilepsy Using a Flexible Dose-escalation Schedule and Individualized Maintenance Doses |
Completed |
NCT01235403 |
Phase 4 |
Lacosamide |
24 |
A Phase IV, Prospective, Open-Label, Parallel Study Evaluating the Effect of an Adjunctive Anti-Seizure Medication Using a Glutamatergic Modulator in Patients With Focal Epilepsy and High-Grade Glioma |
Recruiting |
NCT04650204 |
Phase 4 |
Anticonvulsant Agent;Perampanel |
25 |
Study of the Interest of the Combination of Stiripentol (Diacomit®) and Carbamazepine in the Treatment of Patients With Pharmacoresistant Focal Epilepsies |
Recruiting |
NCT05419180 |
Phase 4 |
Stiripentol |
26 |
Exploratory Open-Label Study of Effects on Responsive Neurostimulator Activity After Intranasal Administration of Single Dose of Valtoco® to People With Epilepsy |
Not yet recruiting |
NCT05273398 |
Phase 4 |
nasal diazepam |
27 |
"Rational Polytherapy" Using Perampanel Dual Therapy Anticonvulsant Combination Treatments of Adults With Refractory Focal Epilepsy : a Pilot Study. |
Terminated |
NCT02727101 |
Phase 4 |
perampanel |
28 |
An Open Prospective Randomised Long-Term Effectiveness Study, Comparing Best Medical Practice With or Without Adjunctive VNS Therapy in Patients 16 Years and Older With Pharmaco-resistant Partial Epilepsy |
Terminated |
NCT00522418 |
Phase 4 |
Best Medical Practive |
29 |
An Open Label, Randomized Study Prospectively Examining the Effect on Anxiety in Partial Epilepsy Patients Treated With Pregabalin |
Terminated |
NCT01128712 |
Phase 4 |
Pregabalin |
30 |
Post Marketing Study; Randomized, Parallel-Group Comparison of Treatment With Pharmacotherapy or Adjunctive Vagus Nerve Stimulation Therapy for Pharmacoresistant Partial Seizures: A Large Simple Effectiveness Trial |
Terminated |
NCT00215215 |
Phase 4 |
|
31 |
A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effect of Perampanel on Objective and Subjective Sleep in Subjects With Insomnia and Partial Onset Seizures |
Withdrawn |
NCT02220972 |
Phase 4 |
Perampanel;Placebo |
32 |
A Double-blind, Phase III, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Levetiracetam as Adjunctive Therapy, in Partial Seizures Control Associated With Refractory Focal Epilepsy |
Completed |
NCT01392768 |
Phase 3 |
Levetiracetam;Placebo |
33 |
Clinical and Medico-economical Assessment of Deep Brain Stimulation of the Anterior Nucleus of the Thalamus for the Treatment of Pharmacoresistant Partial Epilepsy |
Completed |
NCT02076698 |
Phase 3 |
Usual treatment |
34 |
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial. |
Completed |
NCT00957684 |
Phase 3 |
eslicarbazepine acetate;placebo |
35 |
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Trial |
Completed |
NCT00988429 |
Phase 3 |
800 mg QD Eslicarbazepine acetate;1200 mg QD Eslicarbazepine acetate;Placebo |
36 |
Efficacy and Safety of BIA 2-093 as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Clinical Trial |
Completed |
NCT00957372 |
Phase 3 |
eslicarbazepine acetate;placebo (Part I);ESL - Open-label Extension (Part II) |
37 |
Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy |
Completed |
NCT00908349 |
Phase 3 |
Oxcarbazepine XR |
38 |
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures |
Completed |
NCT02535091 |
Phase 3 |
YKP3089 |
39 |
Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children |
Completed |
NCT00988156 |
Phase 3 |
Eslicarbazepine acetate (BIA 2-093);Eslicarbazepine acetate |
40 |
Efficacy and Safety of BIA 2-093 as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial |
Completed |
NCT00957047 |
Phase 3 |
eslicarbazepine acetate;placebo;ESL - Part II |
41 |
Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs |
Completed |
NCT00866775 |
Phase 3 |
Eslicarbazepine acetate |
42 |
A Randomized, Multi-centre, Double-blind Study, to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy |
Completed |
NCT00477295 |
Phase 3 |
Zonisamide;Carbamazepine |
43 |
A Korean Open-label, Multi-center, Community-based Trial Assessing the Efficacy and Safety of Levetiracetam as Adjunctive Therapy in Adult Subjects With Uncontrolled Partial Epilepsy for Bridging Purpose With a Similar Study on Caucasian Epileptic Subjects |
Completed |
NCT00160628 |
Phase 3 |
Levetiracetam |
44 |
Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs |
Completed |
NCT01091662 |
Phase 3 |
Eslicarbazepine acetate 1600 mg;Eslicarbazepine acetate 1200 mg |
45 |
Pregabalin BID Add-on Trial: a Randomized, Double-Blind, Placebo-Controlled Parallel-Group Single-Center Sleep EEG Study in Patients With Partial Seizures and Sleep Disturbance Part B: a Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of Pregabalin Add-on Treatment |
Completed |
NCT00643136 |
Phase 3 |
Pregabalin;Placebo |
46 |
Phase III Study to Evaluate the Efficacy and Safety of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Seizures |
Completed |
NCT00772603 |
Phase 3 |
Placebo;2400mg SPN-804;1200mg SPN-804 |
47 |
A 12-month Open-label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Pregabalin In Pediatric Patients With Partial Onset Seizures |
Completed |
NCT00448916 |
Phase 3 |
Pregabalin |
48 |
A Multicenter, Rater-blind, Randomized, Age-stratified, Parallel-group Study Comparing Two Doses of Oxcarbazepine as Adjunctive Therapy in Pediatric Patients With Inadequately-controlled Partial Seizures. |
Completed |
NCT00050934 |
Phase 3 |
oxcarbazepine |
49 |
A Multicenter, Open-label Trial to Investigate the Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures With or Without Secondary Generalization. |
Completed |
NCT00151879 |
Phase 2, Phase 3 |
SPM 927 |
50 |
Pregabalin BID Open-Label Add-On Trial: A Follow-Up Study To Determine Long-Term Safety and Efficacy in Patients With Partial Seizures |
Completed |
NCT00143143 |
Phase 3 |
Pregabalin |
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
clorazepate
Clorazepate Dipotassium
ezogabine
gabapentin
gabapentin enacarbil
lamotrigine
Levetiracetam
Lorazepam
Oxazepam
|
oxcarbazepine
Phenobarbital
Phenobarbital Sodium
Prazepam
tiagabine
Tiagabine hydrochloride
topiramate
zonisamide
|
|